Top Page
Mayne Pharma Group
(OTC:MYX)
Mayne Pharma Group (MYX) vs. iShares MSCI Australia ETF (EWA)
Mayne Pharma Group Business Overview & Revenue Model
Mayne Pharma Group Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 408.10M | 408.10M | 388.15M | 183.59M | 157.15M | 400.78M |
| Gross Profit | 247.27M | 247.27M | 218.53M | 26.84M | 23.75M | 127.02M |
| EBITDA | 42.08M | 42.08M | -116.93M | -193.80M | -78.88M | -182.40M |
| Net Income | -93.84M | -93.84M | -174.23M | 117.25M | -281.29M | -208.42M |
Balance Sheet | ||||||
| Total Assets | 1.01B | 1.01B | 1.14B | 1.25B | 1.30B | 1.48B |
| Cash, Cash Equivalents and Short-Term Investments | 100.40M | 100.40M | 149.28M | 220.14M | 97.08M | 98.35M |
| Total Debt | 41.27M | 41.27M | 38.82M | 47.51M | 413.67M | 346.82M |
| Total Liabilities | 644.32M | 644.32M | 688.99M | 613.77M | 764.89M | 706.56M |
| Stockholders Equity | 370.28M | 370.28M | 454.19M | 634.36M | 545.88M | 768.36M |
Cash Flow | ||||||
| Free Cash Flow | 5.19M | 5.19M | -36.16M | -262.71M | -28.47M | 22.16M |
| Operating Cash Flow | 17.47M | 17.47M | -15.30M | -43.12M | -16.62M | 47.26M |
| Investing Cash Flow | -68.07M | -68.07M | 53.45M | 473.49M | -28.53M | -49.25M |
| Financing Cash Flow | -4.00M | -556.00K | -19.85M | -431.48M | 27.60M | -28.83M |
Mayne Pharma Group Technical Analysis
Mayne Pharma Group Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | AU$373.99M | 23.83 | 22.84% | 0.88% | 21.47% | 89.09% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$105.58M | -7.86 | -31.98% | ― | 34.20% | -23.90% | |
49 Neutral | AU$648.44M | -10.43 | -35.86% | ― | ― | -19.21% | |
48 Neutral | AU$321.21M | -22.48 | -83.97% | ― | 1271.12% | 36.87% | |
46 Neutral | AU$1.24B | -16.52 | -54.37% | ― | ― | -29.93% | |
38 Underperform | AU$230.74M | -2.46 | -21.13% | ― | 5.07% | 46.14% |
Mayne Pharma Group Corporate Events
Mayne Pharma Group has received a formal notice of appeal from Cosette Pharmaceuticals and its BidCo lodged with the New South Wales Court of Appeal, challenging a prior Supreme Court judgment that had found in favour of Mayne Pharma. The appeal targets the court’s findings on Mayne Pharma’s FY25 EBITDA, which was central to Cosette’s misleading and deceptive conduct claim, and on Cosette’s allegation that a material adverse change had occurred based on Q3 FY25 sales metrics; Mayne Pharma has indicated it is reviewing the appeal and intends to vigorously defend the earlier ruling, signalling a continued legal overhang that could influence perceptions of the company’s financial performance and deal-related risk among investors and other stakeholders.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group has announced that director Frank Charles Condella Jr has ceased to be a director of the company effective 14 January 2026. At the time of his departure, Condella held 65,929 ordinary shares in Mayne Pharma, and the company reported no additional indirect security holdings or contractual interests linked to his role, indicating a straightforward change in board composition without disclosed related-party or contractual complexities.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group has announced a streamlining of its board, with long-serving chair Frank Condella retiring effective 14 January 2026 and non-executive directors Patrick Blake and Anne Lockwood set to step down following the release of the company’s half-year results in February 2026. Professor Bruce Robinson, a non-executive director since 2014 with extensive governance and healthcare sector experience, has been appointed non-executive chair, while the board continues to review its composition to ensure it has the skills and expertise needed to drive shareholder value; the company has also recommended shareholders support the re-election of directors Ann Custin and David Petrie at the upcoming annual general meeting.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group Limited has issued 1,090,360 unquoted performance rights under its employee incentive scheme, effective 30 December 2025. The new equity-based awards, which are subject to transfer restrictions and will not be quoted on the ASX until those restrictions lapse, underscore the company’s ongoing use of long-term incentives to align employee and executive interests with shareholder value and support retention in a competitive pharmaceutical talent market.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group Limited has notified the market of the issue of 25,592 new ordinary fully paid shares following the conversion or exercise of previously unquoted equity securities, effective 31 December 2025. The modest increase in issued capital reflects the crystallisation of existing equity incentives or convertible instruments, marginally diluting existing shareholders while signalling ongoing utilisation of equity-based funding and remuneration typical for companies in the pharmaceutical sector.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group has notified the market that 100,543 performance rights have lapsed after the conditions attached to those rights were not satisfied by the 30 December 2025 deadline. The cessation of these securities reduces the company’s potential future share issuance under its incentive arrangements and may slightly lessen prospective dilution for existing shareholders, while also indicating that certain performance hurdles or targets tied to management or employee incentives were not met.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group has disclosed changes in the holdings of director Shawn Patrick O’Brien, reflecting the exercise of performance rights and restricted stock unit (RSU) performance rights under the company’s Performance Rights and Option Plan. Between 16 and 18 December 2025, O’Brien exercised a substantial number of performance rights, resulting in the acquisition of 326,452 ordinary shares and the disposal of 35,170 RSU performance rights and 364,103 performance rights, some through exercise and others forfeited for not meeting vesting conditions, with a portion of the resulting shares sold on-market to cover tax obligations. Following these transactions, O’Brien now holds 568,193 performance rights and 37,041 ordinary shares directly, and 220,532 ordinary shares indirectly through the plan custodian, signalling a shift from derivative-style incentives into a larger direct and indirect equity stake in the company.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group has notified the market that 241,192 performance rights (ASX code: MYXAN) have lapsed after the conditions attached to these conditional rights were not met or became incapable of being satisfied as of 16 December 2025. The cessation of these securities effectively reduces the company’s potential future share dilution under its incentive arrangements and may signal that certain performance or vesting hurdles tied to these rights were not achieved, which could be relevant for investors tracking executive or employee equity incentives and capital structure dynamics.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group Limited has issued 1,356,532 new fully paid ordinary shares following the exercise or conversion of previously unquoted options or other convertible securities, with an effective issue date of 22 December 2025. The move modestly increases the company’s share capital base and reflects the crystallisation of equity-based incentives or financing instruments, which may slightly dilute existing shareholders while signalling ongoing engagement of option and convertible security holders with the company’s equity.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma has confirmed details for its 2025 Annual General Meeting, which will be held in hybrid format at a Melbourne venue and online on 29 January 2026, following an extension of time granted by the corporate regulator. Shareholders will be asked to consider the company’s statutory reports for the year ended 30 June 2025, vote on the re-election of directors, adopt the 2025 remuneration report and approve a long-term incentive grant of performance rights to the CEO and managing director, with the meeting positioned as a key forum for engagement on management, governance and executive pay.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma reported a mixed unaudited trading update for the first five months of FY26, with group net revenue down 5.5% to $165 million and underlying EBITDA roughly halved to $11.5 million amid higher marketing spend, FDA post-approval study costs and pricing pressure in parts of its dermatology portfolio. While total direct contribution slipped 7.3% to $49.7 million, the company highlighted strong prescription and volume growth across its women’s health franchise, improved gross margins in dermatology driven by TWYNEO and EPSOLAY, and stronger international gross margins, underpinned by Australia’s PBS listing for NEXTSTELLIS, expected US regulatory tailwinds for BIJUVA and IMVEXXY, and ongoing investment in sales, marketing and domestic manufacturing as the board reviews strategic options to maximise long-term shareholder value.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma has officially opened its expanded manufacturing facility in Salisbury, South Australia, which has been modernized with an $18 million investment. The facility, supported by a $4.8 million government grant, enhances production efficiency and capacity, positioning the company for new product launches and exports, and contributing to a 7% revenue increase in FY25.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma has terminated its Scheme Implementation Deed (SID) with Cosette due to material breaches by Cosette, which Mayne Pharma deemed willful and intentional. This termination releases Mayne Pharma from the restrictions of the SID and does not obligate them to pay a break fee. The company is considering further actions regarding Cosette’s breaches and has notified Cosette of its intention to enforce a costs order made against them. Mayne Pharma will keep its shareholders informed of any further developments related to this termination.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma has received a notice from Cosette Pharmaceuticals purporting to terminate their Scheme Implementation Deed (SID) due to unmet conditions. However, Mayne Pharma disputes the validity of this termination, arguing that Cosette’s failure to meet its obligations under the SID contributed to the unmet conditions. The company has reserved its rights regarding Cosette’s non-compliance, potentially impacting the future of their collaboration and market positioning.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group Limited has issued a notice of intention to terminate the Scheme Implementation Deed with Cosette Pharmaceuticals due to material breaches by Cosette. These breaches include failing to meet obligations related to FIRB approval and debt financing, which could impact the proposed acquisition. Mayne Pharma reserves the right to terminate the agreement if the breaches are not resolved within five business days, potentially affecting its strategic plans and stakeholder interests.
The most recent analyst rating on (AU:MYX) stock is a Sell with a A$3.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group announced that its proposed acquisition by Cosette Pharmaceuticals is unlikely to proceed due to the objection from the Foreign Investment Review Board (FIRB). The scheduled court hearing has been vacated, and Mayne Pharma is assessing its options and next steps while consulting with Cosette on available alternatives. This development impacts the company’s strategic plans and may affect stakeholders’ expectations.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group Limited has requested a trading halt on its securities pending a significant announcement regarding a proposed acquisition by Cosette through a scheme of arrangement. This move indicates a strategic shift that could potentially impact the company’s market positioning and stakeholder interests.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma has announced an update on its proposed acquisition by Cosette Pharmaceuticals, with the Foreign Investment Review Board extending its approval deadline to November 21, 2025. The company has rescheduled the court hearing to approve the scheme of arrangement to November 23, 2025. The acquisition remains contingent on FIRB and court approvals, among other conditions. If approved, Mayne Pharma shares will be suspended from trading on November 24, 2025, marking a significant shift in its market presence.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
The Panel declared unacceptable circumstances in Mayne Pharma’s dealings with Cosette Pharmaceuticals, Inc., following Cosette’s change of intentions regarding the Salisbury Site. This decision impacts the market’s perception of the control over Mayne Pharma, highlighting concerns about competitive and informed market principles. The Panel’s orders require Cosette to comply with conditions related to the Salisbury Site, ensuring transparency and adherence to initial disclosures.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group Limited is navigating the approval process for its acquisition by Cosette Pharmaceuticals, which is contingent on the Foreign Investment Review Board’s (FIRB) decision. The FIRB has extended its decision deadline to 20 November 2025, and Cosette’s current debt arrangements are only available if the scheme becomes effective by 24 November 2025. The scheme’s progression is not dependent on Cosette’s current debt facilities, and Mayne Pharma is committed to enforcing its rights under the Scheme Implementation Deed. The company is closely monitoring the situation as the Second Court Hearing is scheduled for 21 November 2025, which will determine the scheme’s effectiveness by the new deadline.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group Limited has initiated proceedings with the Takeovers Panel regarding its affairs, specifically concerning the Scheme Implementation Deed with Cosette Pharmaceuticals, Inc. The Panel has issued interim orders to amend the End Date in the Deed to 24 November 2025, preventing Cosette from terminating the agreement without prior consent. This action aims to maintain the status quo while the Panel considers the application, impacting the ongoing merger process between Mayne and Cosette.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group Limited has requested a trading halt on its securities pending the release of a material announcement regarding a proposed acquisition by Cosette through a scheme of arrangement. This move is expected to have significant implications for the company’s operations and market positioning, as it could potentially lead to strategic realignment and impact stakeholders involved.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group Limited announced an update regarding its proposed acquisition by Cosette Pharmaceuticals, with the Foreign Investment Review Board extending the statutory deadline for approval to 17 November 2025. The acquisition scheme remains contingent on FIRB and court approvals, among other conditions, but the indicative timetable remains unchanged. Shareholders are advised that no action is required from them at this time.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
The FDA’s decision to remove the ‘black box’ warnings from hormone replacement therapies (HRTs) marks a significant regulatory change that is expected to enhance prescribing practices, boost patient and physician confidence, and expand the market for women’s health therapies. This change could reduce stigma and hesitation around HRT, potentially unlocking new patient segments and increasing the utilization of Mayne Pharma’s HRT products, BIJUVA® and IMVEXXY®, thereby driving commercial execution and delivering greater value for patients.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group Limited is currently involved in legal proceedings with Cosette Pharmaceuticals regarding a proposed acquisition scheme. The Supreme Court of New South Wales ruled in favor of Mayne Pharma, dismissing Cosette’s claims, but Cosette has filed a notice of intention to appeal. Mayne Pharma is taking steps to implement the acquisition scheme, which remains subject to certain conditions, including court and regulatory approvals. The company is also considering measures to expedite the appeal process and will update the market on any changes to the acquisition timeline.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group Limited has received an extension from the Australian Securities and Investments Commission to delay its 2025 Annual General Meeting until January 2026. This extension aligns with the anticipated timeline for the company’s acquisition by Cosette Pharmaceuticals, contingent on fulfilling certain conditions, including FIRB and Court approvals. If the acquisition proceeds as planned, Mayne Pharma will not need to hold an AGM as it will have only one shareholder. The outcome of this acquisition could significantly impact Mayne Pharma’s operational structure and market positioning.
The most recent analyst rating on (AU:MYX) stock is a Sell with a A$4.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group announced that the Foreign Investment Review Board (FIRB) has extended the deadline for approval of its acquisition by Cosette Pharmaceuticals to 14 November 2025. The acquisition, structured as a scheme of arrangement, still requires FIRB and court approvals. If approved, Mayne Pharma shares will be suspended from trading on 19 November 2025, with the scheme implementation date set for 1 December 2025. The extension may impact the timeline of the acquisition, but Mayne Pharma will keep stakeholders informed of any changes.
The most recent analyst rating on (AU:MYX) stock is a Sell with a A$4.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group Limited has submitted an application to the Panel regarding its affairs, following a series of events related to its acquisition by Cosette Pharmaceuticals, Inc. The acquisition, valued at $7.40 per share, faced challenges including allegations of a Material Adverse Change and issues with continuous disclosure obligations. Despite these challenges, the NSW Supreme Court ruled in favor of Mayne, invalidating Cosette’s termination notices. However, the acquisition’s future remains uncertain as the Treasurer expressed concerns that it may negatively impact the Australian economy and community, potentially affecting the national interest.
The most recent analyst rating on (AU:MYX) stock is a Sell with a A$4.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group Limited has announced updates regarding the Foreign Investment Review Board (FIRB) approval and the proposed scheme of arrangement for Cosette Australia BidCo Pty Ltd to acquire all shares in the company. The Supreme Court of New South Wales has rescheduled the hearing to approve this scheme to 18 November 2025, pending FIRB approval. The FIRB has extended its statutory deadline, and if approval is received before 14 November 2025, Mayne Pharma may request an earlier court date. Shareholders have the right to oppose the scheme at the court hearing, which is crucial for the acquisition process and could significantly impact Mayne Pharma’s future operations and market positioning.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$4.00 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group Limited is facing potential challenges in its proposed acquisition by Cosette Pharmaceuticals, as the Australian Treasurer has expressed preliminary concerns that the acquisition may not be in the national interest due to potential negative impacts on the Australian economy and community. The Treasurer is particularly concerned about the potential closure of Mayne Pharma’s manufacturing site in Adelaide, which plays a significant role in Australia’s pharmaceutical manufacturing and research capabilities. Mayne Pharma has invested heavily in this site and disagrees with the commercial rationale for its closure. The company is actively engaging with Cosette to address these concerns and expedite the approval process, while also keeping shareholders informed of developments.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$6.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group Limited has announced the cessation of 5,503 performance rights due to unmet conditions, as of October 28, 2025. This announcement may impact the company’s operational strategy and stakeholder interests, reflecting a potential shift in how performance incentives are managed within the organization.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$6.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
UBS Group AG and its related bodies corporate have ceased to be substantial shareholders of Mayne Pharma Group Limited as of October 16, 2025. This change in shareholder status may impact Mayne Pharma’s market dynamics and investor relations, as substantial shareholders often have significant influence over company decisions.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$6.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.